Stay updated with breaking news from Solid Tumors. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The observational BASECAMP-1 screening study has started to identify patients with advanced solid tumors harboring somatic human leukocyte antigen-A*02 loss of heterozygosity who would be eligible to receive the novel Tmod CAR T-cell therapy, A2B530, if their cancer relapses after standard of care treatment.
BACKGROUND: Programmed cell death receptor-1 (PD-1)-blocking antibodies are approved to treat metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) cases ineligible for curative surgery or radiation. Notwithstanding, some patients experience inadequate responses or severe immune-related adverse events (AEs), indicating the need for improved therapies. Cosibelimab is a high-affinity programmed cell death-ligand 1 (PD-L1)-blocking antibody that activates innate and adaptive immunity by blocking PD-L1 interaction with PD-1 and B7-1 receptors. It is an unmodified immunoglobulin G...
The approval is based on the pivotal TRIDENT-1 trial, in which Augtyro successfully achieved a high objective response rate and durable response1 Augtyro adds to Bristol Myers Squibb’s growing...
$2.5 billion global licensing, co-development, and commercialization agreement expands worldwide potential of novel radioenhancer NBTXR316.9 months median progression free survival (mPFS) and 23.1 months median overall survival (mOS) following radiotherapy-activated
SHANGHAI, Nov. 6, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ('Abbisko Therapeutics' hereafter) announced that two major clinical updates...